US-based Anixa Biosciences has commercially launched Cchek Prostate Cancer Confirmation (Cchek PCC) test.
The low-cost blood test said to accurately detect the existence of cancer by measuring the body’s immune response to malignancy by analysing immune system cells in peripheral blood.
The test has been developed with the Cchek artificial intelligence-driven, flow cytometry-based, liquid biopsy technology platform.
Data suggests that over 90% of prostate biopsies conducted in the US are negative. The test is designed to minimise invasive procedures and cut healthcare costs associated with conventional methods of diagnosing prostate cancer.
Anixa CEO Amit Kumar said: “This is a major milestone for Anixa and our partner-based business model. From the start, our goal with Cchek has been to develop an inexpensive blood test that accurately detects the existence of cancer by measuring the body’s immune response.”
Anixa Biosciences will offer it as a CLIA validated test through its partner laboratory ResearchDx.
Kumar said: “In the coming months, we expect to conduct a number of activities to support the marketing of Cchek PCC, including the development of marketing materials, education of key opinion leaders in urology, and development of a reimbursement path for the test. We expect Cchek PCC to be broadly available throughout the US by April 2020.”
To date, Anixa used Cchek technology to detect the presence of 20 different cancers, including lung, colon, breast and prostate.